Filippo Mori

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 7

Top Topics

Platelet Rich Plasma

Acute Respiratory Distress Syndrome

Top Venues

Pharmaceuticals (Basel, Switzerland)

International journal of laboratory hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Filippo Mori, Cristina Angelini, Claudio Farina
New plasma protein C and protein S concentrate: A synergy for therapeutic purposes. Vox sanguinis (2023)
Lucia Vizzoni, Chiara Migone, Brunella Grassiri, Ylenia Zambito, Baldassare Ferro, Paolo Roncucci, Filippo Mori, Alfonso Salvatore, Ester Ascione, Roberto Crea, Semih Esin, Giovanna Batoni, Anna Maria Piras
Biopharmaceutical Assessment of Mesh Aerosolised Plasminogen, a Step towards ARDS Treatment. Pharmaceutics 15 (6) (2023)
Lucia Vizzoni, Chiara Migone, Brunella Grassiri, Ylenia Zambito, Baldassare Ferro, Paolo Roncucci, Filippo Mori, Alfonso Salvatore, Ester Ascione, Roberto Crea, Semih Esin, Giovanna Batoni, Anna Maria Piras
Biopharmaceutical Assessment of Mesh Aerosolised Plasminogen, a Step towards ARDS Treatment. Pharmaceutics 15 (6) (2023)
Filippo Mori, Cristina Genuardo, Silvia Nannizzi, Claudio Farina
Intra- and interassay variations of two thrombin generation methods. International journal of laboratory hematology 43 (4) (2021)
Filippo Mori, Alfonso Salvatore, Ester Ascione, Raffaele Di Marzo, Bernard J Fox
Evaluation of prophylactic polyclonal anti-D antibodies: Differences in Fc-glycosylation in commercial products. Vox sanguinis (2021)
Filippo Mori, Ilaria Nardini, Andrea Caricasole, Novinyo Serge Amega, Claudio Farina
Characterization of a plasma-derived double-viral-inactivated factor VIII concentrate (antihaemophilic factor [human]): Focus on TTP treatment. Haemophilia : the official journal of the World Federation of Hemophilia 27 (3) (2021)
Anna Maria Piras, Ylenia Zambito, Maurizio Lugli, Baldassare Ferro, Paolo Roncucci, Filippo Mori, Alfonso Salvatore, Ester Ascione, Marta Bellini, Roberto Crea
Repurposing of Plasminogen: An Orphan Medicinal Product Suitable for SARS-CoV-2 Inhalable Therapeutics. Pharmaceuticals (Basel, Switzerland) 13 (12) (2020)